Byetta (exenatide)
- Region
- 🇪🇺 EU
- Active substance
- exenatide
- Company
- AstraZeneca AB
- Status
- Withdrawn
- Therapeutic area
- Diabetes Mellitus, Type 2
- EU approval
- Mon 20 Nov 2006
- Application
- EMEA/H/C/000698
- ATC
- A10BJ01
- Official record
- www.ema.europa.eu
Indication
Byetta is indicated for treatment of type-2 diabetes mellitus in combination with: metformin; sulphonylureas; thiazolidinediones; metformin and a sulphonylurea; metformin and a thiazolidinedione; in adults who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies. Byetta is also indicated as adjunctive therapy to basal insulin with or without metformin and / or pioglitazone in adults who have not achieved adequate glycaemic control with these agents.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Bydureon Withdrawn · AstraZeneca AB
Follow Byetta
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.